SCHEMBL30765445

SCHEMBL30765445

C[C@@H](Nc1cnc(N2CCCCC2)n(CC(=O)O)c1=O)c1nc(-c2ccccc2)co1

nearest known ligand 0.37

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
AKT1 P31749 6/20 0.37
AKT2 P31751 6/20 0.37
AKT3 Q9Y243 6/20 0.37
ALDH1A1 P00352 5/20 0.36
PHGDH O43175 1/20 0.36
IDH1 O75874 1/20 0.34
TSHR P16473 3/20 0.33
LMNA P02545 2/20 0.33
PIK3CA P42336 2/20 0.33
MAPT P10636 2/20 0.33
MAPK13 O15264 1/20 0.33
MAPK12 P53778 1/20 0.33
MAPK11 Q15759 1/20 0.33
MAPK14 Q16539 1/20 0.33
NPSR1 Q6W5P4 1/20 0.33
KDM4E B2RXH2 1/20 0.33
ELANE P08246 1/20 0.33
MEN1 O00255 1/20 0.33
USP2 O75604 1/20 0.33
ALOX15 P16050 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31558527 0.93 AKT1 (0.36) AKT1AKT2AKT3ALDH1A1PHGDH
SCHEMBL30765998 0.90 ALDH1A1 (0.35) AKT1AKT2AKT3ALDH1A1PHGDH
SCHEMBL30765621 0.88 GAA (0.42) ALDH1A1TSHRLMNAMAPTNPSR1
SCHEMBL30766001 0.82 AKT1 (0.36) AKT1AKT2AKT3ALDH1A1PHGDH
SCHEMBL30765435 0.82 F2 (0.36) AKT1AKT2AKT3IDH1TSHR
SCHEMBL30765622 0.80 IDH1 (0.38) AKT1AKT2AKT3ALDH1A1PHGDH
SCHEMBL30765713 0.79 AKT1 (0.36) AKT1AKT2AKT3ALDH1A1IDH1
SCHEMBL30765827 0.79 AKT1 (0.36) AKT1AKT2AKT3ALDH1A1IDH1
SCHEMBL30765552 0.78 LMNA (0.38) ALDH1A1LMNAPIK3CAKDM4EL3MBTL1
SCHEMBL31558437 0.76 AKT1 (0.35) AKT1AKT2AKT3ALDH1A1PHGDH

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4568666-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS Alexion Pharmaceuticals, Inc. (US) 2025-06-18 EP disclosed
CN-119768164-A Pharmaceutical compounds for treating complement-mediated disorders 阿雷克森制药公司 2025-04-04 CN disclosed
WO-2024035686-A1 PHARMACEUTICAL COMPOUNDS FOR THE TREATMENT OF COMPLEMENT MEDIATED DISORDERS ALEXION PHARMACEUTICALS, INC. (US) 2024-02-15 WO disclosed